A single dose of an ALVAC vector based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats, and dogs

In this article, the authors developed a potential rabies vaccine, ALVAC-RABV-VLP, using CRISPR/Cas9 gene editing technology to reduce vaccine costs and provide a new and safer method of combating the highly fatal zoonotic disease. The vaccine, which uses a canarypox virus vector, was found to be highly potent in mice, cats, and dogs, eliciting a durable and effective humoral immune response compared to commercial ones. The ALVAC-RABBV-VLP effectively activated dendritic cells, follicular T helper cells, and germinal center / plasma cells. The survival rate was 100% in mice challenged with a lethal dose of RABV.

(SN)